Gene modified enhanced MSCs, as a second-generation product, has the dual advantages of cell therapy and gene therapy. The company has signed a cooperation framework agreement with Academician Zhong Nanshan's team of Guangzhou Institute of Respiratory Health, which will carry out basic and clinical research on mesenchymal stem cells in the treatment of pulmonary injury diseases such as idiopathic pulmonary fibrosis and chronic obstructive pulmonary disease etc..
